- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05208047
(Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal Tumors
Estudio clínico de fase 3, aleatorizado, abierto, multicéntrico de CGT9486+sunitinib frente a sunitinib en sujetos con tumores del estroma gastrointestinal localmente avanzados, irresecables o metastásicos
This is a Phase 3, open-label, international, multicenter study of bezuclastinib in combination with sunitinib. This is a multi-part study that will enroll approximately 482 participants. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of bezuclastinib to be used in subsequent parts in approximately 20 participants who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between bezuclastinib and sunitinib in approximately 18 participants who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 participants who are intolerant to, or who failed prior treatment with imatinib only and will compare the efficacy of bezuclastinib plus sunitinib to sunitinib alone with participants being randomized in a 1:1 manner. This study also contains two substudies: 1) a drug-drug interactions (DDI) substudy will investigate the potential for bezuclastinib to be a Cytochrome P450 (CYP)3A4 inducer in approximately 16 participants who have received at least one prior line of therapy for GIST and 2) a substudy intended to test the efficacy of bezuclastinib and sunitinib as first-line (1L) treatment of GIST in approximately 40 participants with KIT exon 9 mutations and no prior systemic therapy (with the exception of up to 10 participants with ongoing imatinib therapy of ≤4 weeks).
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Cogent Biosciences
- Número de teléfono: 617-945-5576
- Correo electrónico: peakinfo@cogentbio.com
Ubicaciones de estudio
-
-
-
Bad Saarow, Alemania, 15526
- Activo, no reclutando
- Helios Klinikum Bad Saarow
-
Berlin, Alemania, 13125
- Activo, no reclutando
- Helios Klinikum Berlin-Buch
-
Essen, Alemania, 45147
- Activo, no reclutando
- Universitaetsklinikum Essen
-
Hamburg, Alemania, 20246
- Activo, no reclutando
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover, Alemania, 30625
- Activo, no reclutando
- Medizinische Hochschule Hannover- Urology Oncology
-
Mannheim, Alemania, 68167
- Activo, no reclutando
- Universitaetsmedizin Mannheim
-
-
-
-
-
Buenos Aires, Argentina, C1426ANZ
- Activo, no reclutando
- Instituto Alexander Fleming
-
Córdoba, Argentina, X5000HWE
- Activo, no reclutando
- Instituto Oncologico de Cordoba (IONC)
-
-
-
-
-
Bankstown, Australia, 2200
- Activo, no reclutando
- Bankstown-Lidcombe Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Activo, no reclutando
- Sir Charles Gairdner Hospital
-
-
-
-
-
Campinas, Brasil, 130.83-888
- Activo, no reclutando
- Hospital das Clinicas da Universidade Estadual de Campinas (UNICAMP)
-
Rio de Janeiro, Brasil, 20.230-130
- Activo, no reclutando
- lnstituto Nacional de Cancer - INCA
-
São Paulo, Brasil, 09060-650
- Activo, no reclutando
- CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
-
-
-
-
-
Calgary, Canadá, T2N 4N2
- Reclutamiento
- Tom Baker Cancer Center
-
Montreal, Canadá, HIT 2M4
- Activo, no reclutando
- Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR)
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Reclutamiento
- Alberta Health Services Cross Cancer Institute
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- Princess Margaret Hospital
-
-
-
-
-
Brno, Chequia, 65653
- Activo, no reclutando
- Masarykuv onkologicky ustav
-
Hradec Králové, Chequia, 500 05
- Retirado
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Chequia, 77900
- Activo, no reclutando
- Fakultni nemocnice Olomouc - Oncology clinic
-
-
-
-
-
Santiago, Chile, 7500921
- Activo, no reclutando
- Instituto Oncologico FALP
-
Santiago, Chile, 7560908
- Activo, no reclutando
- Centro de Oncologia de Precision, Universidad Mayor
-
-
-
-
-
Seoul, Corea del Sur, 03080
- Activo, no reclutando
- Seoul National University Hospital
-
Seoul, Corea del Sur, 06351
- Activo, no reclutando
- Samsung Medical Center
-
Seoul, Corea del Sur, 08308
- Activo, no reclutando
- Korea University Guro Hospital
-
Seoul, Corea del Sur, 05505
- Activo, no reclutando
- Asan Medical Center
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Corea del Sur, 10408
- Retirado
- National Cancer Center
-
-
-
-
-
Aarhus, Dinamarca, 8200
- Activo, no reclutando
- Aarhus University Hospital
-
-
-
-
-
Barcelona, España, 08035
- Activo, no reclutando
- Hospital Universitario Vall d'Hebron
-
Barcelona, España, 08041
- Retirado
- Hospital de la Santa Creu i Sant Pau Barcelona
-
Barcelona, España, 08908
- Activo, no reclutando
- Institut Catala d'Oncologia - L'Hospitalet
-
El Palmar, España, 30120
- Retirado
- Hospital Clinico Universitario Virgen de la Arrixaca
-
Madrid, España, 28041
- Activo, no reclutando
- Hospital Universitario 12 de Octubre
-
Madrid, España, 28040
- Activo, no reclutando
- Hospital Clinico San Carlos
-
Madrid, España, 28007
- Activo, no reclutando
- Hospital General Universitario Gregorio Maranon
-
Madrid, España, 28040
- Activo, no reclutando
- Hospital Fundación Jiménez Díaz
-
Santiago de Compostela, España, 15706
- Activo, no reclutando
- Hospital Clinico Universitario de Santiago de Compostela
-
Seville, España, 41013
- Activo, no reclutando
- Hospital Universitario Virgen del Rocio
-
Zaragoza, España, 50009
- Retirado
- Hospital Universitario Miguel Servet
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35249
- Retirado
- University of Alabama at Birmingham
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Reclutamiento
- Mayo Clinic
-
Tucson, Arizona, Estados Unidos, 85719
- Activo, no reclutando
- University of Arizona- Cancer Center
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope
-
Los Angeles, California, Estados Unidos, 90404
- Activo, no reclutando
- University of California, Los Angeles (UCLA)
-
San Diego, California, Estados Unidos, 92093
- Reclutamiento
- University of California, San Diego (UCSD)
-
San Francisco, California, Estados Unidos, 94158
- Activo, no reclutando
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80204
- Reclutamiento
- University of Colorado Denver
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Reclutamiento
- MedStar Washington Hospital Center
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224
- Reclutamiento
- Mayo Clinic Jacksonville
-
Miami, Florida, Estados Unidos, 33136
- Reclutamiento
- University of Miami - Sylvester Comprehensive Cancer Center
-
Orange City, Florida, Estados Unidos, 32763
- Retirado
- Mid Florida Hematology and Oncology Center
-
Orlando, Florida, Estados Unidos, 32806
- Reclutamiento
- Orlando Health Cancer Institute
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Hospital and Clinics
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- Activo, no reclutando
- University of Kansas Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63130
- Reclutamiento
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Reclutamiento
- Nebraska Methodist Hospital
-
-
New York
-
Buffalo, New York, Estados Unidos, 14203
- Activo, no reclutando
- Roswell Park Comprehensive Cancer Center
-
New York, New York, Estados Unidos, 10021
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705
- Reclutamiento
- Duke University
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Reclutamiento
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- The Ohio State University Comprehensive Cancer Center
-
Toledo, Ohio, Estados Unidos, 43614
- Retirado
- University of Toledo Medical Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Reclutamiento
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Reclutamiento
- University of Pittsburgh Medical Center - Hillman Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- Retirado
- University of Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Reclutamiento
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-4009
- Reclutamiento
- The University of Texas MD Anderson Cancer Center
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Activo, no reclutando
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53705
- Reclutamiento
- University of Wisconsin - Carbone Cancer Center
-
-
-
-
-
Bordeaux, Francia, 33076
- Activo, no reclutando
- Institut Bergonie
-
Lille, Francia, 59000
- Activo, no reclutando
- Centre Oscar Lambret
-
Lyon, Francia, 69008
- Activo, no reclutando
- Centre Leon Berard
-
Marseille, Francia, 13005
- Activo, no reclutando
- AP-HM - Hôpital de la Timone
-
Rennes, Francia, 35042
- Activo, no reclutando
- Centre Eugene Marquis
-
Saint-Herblain, Francia, 44800
- Activo, no reclutando
- ICO St-Herblain
-
Toulouse, Francia, 31400
- Activo, no reclutando
- CHU de Toulouse - Hospital Rangueil
-
Villejuif, Francia, 94805
- Activo, no reclutando
- Gustave Roussy
-
-
-
-
-
Central, Hong Kong
- Retirado
- Humanity & Health Clinical Trial Centre
-
Jordon, Hong Kong
- Activo, no reclutando
- Hong Kong United Oncology Centre
-
Shatin, Hong Kong
- Activo, no reclutando
- Prince of Wales Hospital
-
-
-
-
-
Debrecen, Hungría, 4032
- Activo, no reclutando
- Debreceni Egyetem, Klinikai Központ, Onkológiai Klinika
-
-
-
-
-
Aviano, Italia, 33081
- Activo, no reclutando
- Centro Riferimento Oncologico - Aviano
-
Bologna, Italia, 40138
- Activo, no reclutando
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola
-
Brescia, Italia, 25123
- Activo, no reclutando
- ASST degli Spedali Civili di Brescia
-
Candiolo, Italia, 10060
- Retirado
- IRCCS La Fondazione e l'Istituto di Candiolo
-
Florence, Italia, 50134
- Activo, no reclutando
- Azienda Ospedaliero-Universitaria Careggi
-
Meldola, Italia, 47014
- Activo, no reclutando
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
-
Milan, Italia, 20133
- Activo, no reclutando
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Italia, 20141
- Activo, no reclutando
- Istituto Europeo di Oncologia
-
Palermo, Italia, 90127
- Activo, no reclutando
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
Roma, Italia, 00128
- Activo, no reclutando
- Policlinico Universitario Campus Bio-Medico
-
Rozzano, Italia, 20089
- Activo, no reclutando
- Istituto Clinico Humanitas
-
Verona, Italia, 31726
- Activo, no reclutando
- Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
-
-
-
-
-
Aguascalientes, México, 20116
- Retirado
- Centro de Investigacion Medica Aquascalientes (CIMA)
-
Monterrey, México, 64710
- Activo, no reclutando
- I Can Oncology Center SA De CV
-
Oaxaca City, México, 68000
- Retirado
- Oaxaca Site Management Organization S.C.
-
-
-
-
-
Bergen, Noruega, 5021
- Activo, no reclutando
- Haukeland University Hospital - Bergen
-
Oslo, Noruega, 0310
- Activo, no reclutando
- Oslo University Hospital
-
-
-
-
-
Amsterdam, Países Bajos, 1066 CX
- Activo, no reclutando
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
-
Groningen, Países Bajos, 9713 GZ
- Activo, no reclutando
- UMC Groningen
-
Nijmegen, Países Bajos, 6525 GA
- Activo, no reclutando
- Stichting Radboud Universitair Medisch Centrum
-
Rotterdam, Países Bajos, 3015 GD
- Activo, no reclutando
- Erasmus MC
-
-
-
-
-
Brzozów, Polonia, 36-200
- Activo, no reclutando
- Szpital Specjalistyczny w Brzozowie
-
Bydgoszcz, Polonia, 85-796
- Retirado
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka
-
Gliwice, Polonia, 44-102
- Activo, no reclutando
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, Oddzial Chemioterapii Dziennej
-
Warsaw, Polonia, 02-781
- Activo, no reclutando
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Activo, no reclutando
- Cambridge Addenbrooke's Hospital
-
Glasgow, Reino Unido, G12 0YN
- Retirado
- Beatson, West of Scotland Cancer Centre
-
London, Reino Unido, NW1 2PG
- Activo, no reclutando
- University College London Hospital
-
London, Reino Unido, SW3 6JJ
- Activo, no reclutando
- Royal Marsden Hospital - Surrey
-
London, Reino Unido, SE1 9RT
- Retirado
- Guy's Hospital
-
Manchester, Reino Unido, M20 4BX
- Activo, no reclutando
- The Christie NHS Foundation Trust
-
Sheffield, Reino Unido, S10 2SJ
- Activo, no reclutando
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
-
Lund, Suecia, 22185
- Activo, no reclutando
- Skane University Hospital Lund
-
Solna, Suecia, 171 76
- Activo, no reclutando
- Karolinska University Hospital
-
-
-
-
-
Kaohsiung City, Taiwán, 83301
- Activo, no reclutando
- Chang Gung Memorial Hospital - Kaohsiung Branch
-
New Taipei City, Taiwán, 10002
- Activo, no reclutando
- National Taiwan University Hospital
-
Taichung, Taiwán, 40447
- Activo, no reclutando
- China Medical University Hospital
-
Taipei, Taiwán, 11217
- Activo, no reclutando
- Taipei Veterans General Hospital (VGHTP)
-
Taoyuan, Taiwán, 33305
- Activo, no reclutando
- Chang Gung Memorial Hospital - Linkou Branch (CGMHLK)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria:
-
Histologically confirmed locally advanced, metastatic, and/or unresectable GIST. Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization. (GIST 1L Substudy: must have documented mutation in KIT Exon 9 with an available molecular pathology report; archival or fresh tumor tissue sample will be required)
-
Documented disease progression on or intolerance to imatinib (Part 1a, Part 1b, Part 2, DDI Substudy)
-
Participants must have received the following treatment:
- DDI Substudy/Part 1a: Treatment with ≥1 prior lines of therapy for GIST
- Part 1b: Treatment with ≥2 prior TKI for GISTs
- Part 2: Prior treatment with imatinib only
- GIST 1L Substudy: No prior systemic therapy for GIST including adjuvant therapy. Exception: up to 10 participants with ongoing imatinib therapy of ≤4 weeks
-
Have at least 1 measurable lesion according to mRECIST v1.1 (Part1a, Part 1b, Part 2, GIST 1L Substudy)
-
Eastern Cooperative Oncology Group (ECOG) Status
- 0 to 2 (Part 1a, Part 1b, Part 2, DDI Substudy)
- 0 to 1 (GIST 1L Substudy)
-
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Key Exclusion Criteria:
- Known Platelet-Derived Growth Factor Receptor (PDGFR) driving mutations or known succinate dehydrogenase deficiency (Part 1a, Part 1b, Part 2, DDI Substudy)
- Clinically significant cardiac disease
- Major surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug (Part 1a, Part 1b, Part 2, DDI Substudy)
- Gastrointestinal abnormalities including, but not limited to, significant nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption
- Any active bleeding excluding hemorrhoidal or gum bleeding
- Seropositive for HIV 1 or 2, or positive for hepatitis B surface antigen or hepatitis C virus (HCV) antibody.
- Active, uncontrolled, systemic bacterial, fungal, or viral infections at Screening
- Received strong CYP3A4 inhibitors or inducers (Part 1a, Part 1b, Part 2, DDI Substudy)
- Received sunitinib within 3 weeks (Part 1a, Part 1b, DDI Substudy)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1a
Bezuclastinib plus sunitinib 37.5 mg once a day (QD) |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 2 - Experimental Group
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Comparador activo: Part 2 - Control Group
Sunitinib 37.5 mg QD |
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 1b - DDI Cohort 1
Bezuclastinib plus sunitinib 37.5 mg QD |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: Part 1b - DDI Cohort 2
Sunitinib 37.5 mg QD plus bezuclastinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
|
Experimental: DDI Substudy (Midazolam)
Midazolam, bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. Participants will receive a single-dose of midazolam on Day 1 and Day 15 |
|
Experimental: GIST 1L Substudy
Bezuclastinib, sunitinib |
Participants will receive bezuclastinib orally until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib orally until study stopping rules are met. Participants will receive bezuclastinib orally starting on Day 2 until study stopping rules are met.
Otros nombres:
Participants will receive bezuclastinib until steady state then both sunitinib and bezuclastinib orally until study stopping rules are met. Participants will receive sunitinib until steady state then both bezuclastinib and sunitinib orally until study stopping rules are met.
Otros nombres:
Participants will receive sunitinib orally starting on Day 16 until study stopping rules are met. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1a - pharmacokinetics - Cmax
Periodo de tiempo: 16 days
|
Maximum plasma concentration (Cmax) |
16 days
|
|
Part 1a - pharmacokinetics - AUC
Periodo de tiempo: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
Part 1b - pharmacokinetics - Cmax
Periodo de tiempo: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
|
Part 1b - pharmacokinetics - AUC
Periodo de tiempo: 14 days
|
Area under the plasma concentration-time curve (AUC) |
14 days
|
|
Part 1b - pharmacokinetics - Tmax
Periodo de tiempo: 14 days
|
Time to maximum observed plasma concentration (Tmax) |
14 days
|
|
Part 2 - Progression Free Survival (PFS)
Periodo de tiempo: Approximately 48 months
|
Time from first dose to documented disease progression or death due to any cause, whichever occurs first |
Approximately 48 months
|
|
DDI Substudy - pharmacokinetics - AUC
Periodo de tiempo: 16 days
|
Area under the plasma concentration-time curve (AUC) |
16 days
|
|
DDI Substudy - pharmacokinetics - Cmax
Periodo de tiempo: 14 days
|
Maximum plasma concentration (Cmax) |
14 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
All Study Parts - observing the safety of each treatment regimen.
Periodo de tiempo: Approximately 48 months
|
Incidence and severity of Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Periodo de tiempo: Approximately 48 months
|
Incidence and severity of Serious Adverse Events from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Periodo de tiempo: Approximately 48 months
|
Incidence of Adverse Events leading to dose modifications from first dose of study drug |
Approximately 48 months
|
|
All Study Parts - observing the safety of each treatment regimen.
Periodo de tiempo: Approximately 48 months
|
Change from baseline in laboratory results |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Overall Survival (OS)
Periodo de tiempo: Approximately 48 months
|
Time from first dose to death due to any cause |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Objective Response Rate (ORR)
Periodo de tiempo: Approximately 48 months
|
Percentage of subjects who achieved documented complete response (CR) + confirmed partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Disease Control Rate (DCR)
Periodo de tiempo: Approximately 48 months
|
Percentage of subjects who achieved CR + PR + stable disease (SD) at 16 weeks |
Approximately 48 months
|
|
Part 1a, Part 1b. Part 2 - Time to response (TTR)
Periodo de tiempo: Approximately 48 months
|
Time from first dose to first documented response based on modified Response Evaluation Criteria in Solid Tumors Version 1.1 |
Approximately 48 months
|
|
Part 1a, Part 1b, Part 2 - Duration of Response (DOR)
Periodo de tiempo: Approximately 48 months
|
Time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first |
Approximately 48 months
|
|
Part 2 Only - European Organisation for Research and Treatment of Cancer Quality of Life (EORTC-QLQ-30)
Periodo de tiempo: Approximately 48 months
|
Change in individual scores in patients with locally advanced, unresectable, or metastatic GIST treated with CGT9486 in combination with sunitinib compared with patients treated with sunitinib monotherapy. The scale comprises 30 questions, 24 of which are aggregated into 9 multi-item scales, to include 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and 1 global health status scale. The remaining 6 single-item scales assess symptoms (dyspnea, appetite loss, sleep disturbance, constipation, diarrhea and the financial impact). All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning, while higher scores on the symptom and single-item scales indicate a higher level of symptoms. |
Approximately 48 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Procesos Neoplásicos
- Neoplasias De Tejidos Conectivos Y Blandos
- Neoplasias Del Tejido Conectivo
- Condiciones Patológicas, Signos y Síntomas
- Metástasis de neoplasias
- Tumores del estroma gastrointestinal
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Azoles
- Indoles
- Benzazepines
- Pirroles
- Benzodiacepinas
- Sunitinib
- Midazolam
Otros números de identificación del estudio
- CGT9486-21-301
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .